• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
OB

External Cephalic Version: Clinical Recommendations and Factors for Success

image_pdfFavoriteLoadingFavorite

SUMMARY:

Breech occurs in approximately 3 to 4% of term pregnancies. The goal of External Cephalic Version (ECV) is to increase the proportion of vertex presentation at term and to decrease the risk of cesarean delivery secondary to breech presentation. Between 20 to 30% of eligible women are not offered this procedure

Timing

  • Fetal presentation should be assessed beginning at 36w0d
  • Preterm ECV has been linked with higher rates of initial success, but increased risk of preterm birth and higher rates of reversion
  • At 37w0d
    • If spontaneous version is going to occur it is likely to have occurred by then
    • Risk of spontaneous reversion is decreased
  • ECV during delivery admission vs breech presentation has a 65% success rate and is associated with
    • Lower cesarean delivery rate
    • Lower likelihood of hospital stay >7 days
  • Limited information in women with preexisting uterine scar or during early stages of labor

Contraindications

  • ECV is contraindicated when vaginal delivery is not clinically appropriate
  • There are no absolute or relative contraindications
    • Evaluate each case individually

Benefits

  • Fewer cesarean deliveries
  • Lower odds of
    • Endometritis | Sepsis | Hospital stay > 7 days
  • Lower hospital charges
  • No differences for
    • Low Apgar | Low umbilical vein pH | Neonatal death

Risks and Adverse effects

  • Most common risk is fetal heart rate changes
    • Typically, heart rate stabilizes when procedure is discontinued
  • Overall serious adverse effects are very low with rates <1%
    • Abruptio placentae | Umbilical cord prolapse | Rupture of membranes | Stillbirth | Fetomaternal hemorrhage
  • Although chance of complications are low, cesarean delivery services should still be readily available
    • Rate of cesarean deliveries due to ECV is low

Factors affecting success

  • Overall success rate approximately 58%
  • Positive association between parity and successful version
  • Transverse or oblique presentation associated with higher immediate success rate
  • Lower success rates at hospitals with higher cesarean rates
  • Factors that might predict success
    • Amniotic fluid volume | Location of placenta | Maternal weight
  • Factors associated with failure
    • Nulliparity | Advanced dilation | Fetal weight < 2500 g | Anterior placenta | Low station

Tocolytic agents

  • Parenteral β stimulants
    • Terbutaline has doubled the rate of ECV success
    • Effective in achieving cephalic presentation
    • Lower rate of failure
    • Data insufficient to analyze adverse effects
  • Nitric oxide
    • Use is discouraged
  • Calcium channel blockers
    • Insufficient data for a recommendation

Analgesia

  • Neuraxial analgesia with tocolysis has a higher incidence of
    • Successful ECV | Cephalic presentation | Vaginal delivery
    • Insufficient data of neuraxial analgesia without tocolysis to make a recommendation
  • Epidural may be considered for women with previous failed ECV attempt

Procedure Considerations

Before ECV

  • Perform ultrasound to confirm malpresentation and rule out abnormalities that would complicate vaginal delivery
  • Inform the patient about benefit and risks of the procedure, tocolysis and analgesia
  • Assess fetal well-being by NST or BPP before and after ECV
  • Cesarean services should be readily available

Performing ECV

  • May be performed by one or two people
  • Lifting the breech upward from the pelvis with one hand and providing pressure on the head with the other hand to produce a forward roll
    • If the forward roll fails, a backward roll may be attempted
  • Intermittent use of ultrasonography during procedure allows evaluation of FHR and position of fetus
  • Abandon attempt if
    • Prolonged fetal bradycardia
    • Patient discomfort
    • Cannot be completed easily

After ECV

  • Repeat fetal evaluation
  • Monitor patient for 30 minutes
  • Administer Anti-D immune globulin to Rh- patients if delivery is not anticipated in the next 72 hours
  • No evidence for routine immediate induction to minimize reversion

KEY POINTS:

  • Fetal presentation should be evaluated beginning at 36w0d
  • All women near term with breech presentation should be offered an ECV attempt if there are no contraindications
  • Evidence supports use of neuraxial analgesia plus tocolysis to increase success
  • Fetal well-being should be assessed before and after ECV and cesarean services should be available

Learn More – Primary Sources:

ACOG Practice Bulletin: External Cephalic Version

image_pdfFavoriteLoadingFavorite
< Previous
All OB Posts
Next >

Related ObG Topics:

Meta-analysis: External Cephalic Version Following Previous Cesarean
External Cephalic Version – 18 Years Experience
Professional Recommendations: Delivery of Breech Presentation at Term
How Does External Cephalic Version Compare to Expectant Management

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site